Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $320.00 Price Target at Oppenheimer

Key Points

• Oppenheimer lowered Alnylam’s price target to $320 from $350 while maintaining an “outperform” rating, implying roughly 94% upside from the prior close.
• Analyst sentiment remains broadly positive but has become more cautious: Alnylam carries a “Moderate Buy” consensus rating with an average target of $325.39, while Bernstein downgraded the stock and several firms reduced their targets.
• Alnylam exceeded third-quarter earnings and revenue expectations, but shares fell to $164.89 amid concerns about slower Amvuttra patient starts, decelerating product growth and uncertainty surrounding its TTR franchise.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target reduced by research analysts at Oppenheimer from $350.00 to $320.00 in a research report issued to clients and investors on Friday. The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Oppenheimer's target price would suggest a potential upside of 94.06% from the company's previous close.

A number of other equities research analysts have also issued reports on the stock. Sanford C. Bernstein lowered shares of Alnylam Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $376.00 to $199.00 in a report on Friday. Cantor Fitzgerald restated a "neutral" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 30th. Jefferies Financial Group increased their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a "hold" rating in a research note on Tuesday, September 8th. BMO Capital Markets reissued an "outperform" rating and set a $290.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, Bank of America reaffirmed a "buy" rating and issued a $287.00 price objective (down from $460.00) on shares of Alnylam Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $325.39.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $9.11 during midday trading on Friday, hitting $164.89. 6,058,994 shares of the company's stock were exchanged, compared to its average volume of 1,507,400. The company has a market cap of $22.06 billion, a P/E ratio of 30.65 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock has a 50-day moving average price of $237.78 and a two-hundred day moving average price of $287.22. Alnylam Pharmaceuticals has a 52-week low of $163.30 and a 52-week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The firm's quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.90 EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of the firm's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president owned 12,807 shares of the company's stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ALNY. Provenance Wealth Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $527,000. GraniteShares Advisors LLC lifted its position in Alnylam Pharmaceuticals by 12.7% during the 3rd quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company's stock worth $450,000 after acquiring an additional 205 shares during the period. Traynor Capital Management Inc. grew its stake in Alnylam Pharmaceuticals by 22.6% during the 3rd quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company's stock valued at $3,163,000 after purchasing an additional 2,360 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $18,226,000. Finally, Profund Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 22.5% in the third quarter. Profund Advisors LLC now owns 16,919 shares of the biopharmaceutical company's stock worth $4,175,000 after purchasing an additional 3,105 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up 16.7% year over year and above expectations. Adjusted earnings of $16.26 per share also exceeded consensus by a wide margin, although much of the earnings surprise was attributed to a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue beat
• Positive Sentiment: The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion to $4.5 billion in 2026 TTR-related sales. Alnylam also continued advancing its RNAi pipeline, including the nucresiran program. Alnylam TTR sales outlook
• Neutral Sentiment: Several analysts lowered their price targets following the results, but most still see potential upside. TD Cowen, Goldman Sachs, RBC and Needham retained positive ratings, while Morgan Stanley and Wells Fargo kept equal-weight ratings. Analyst price-target changes
• Negative Sentiment: Investors were concerned about slower U.S. Amvuttra patient starts and decelerating growth in Amvuttra and Onpattro sales. Those trends raised questions about demand and the durability of Alnylam’s core commercial growth. Demand growth concerns
• Negative Sentiment: Management acknowledged that execution needs to improve as uncertainty grows around the TTR franchise. The expansion of the TRITON-CM heart-disease trial to roughly 2,250 patients reinforced concerns about development costs, timing and the path toward a potential launch around 2030. Uncertainty around Alnylam’s TTR franchise
• Negative Sentiment: Analyst sentiment became more cautious: Bernstein downgraded ALNY to market perform, Stifel cut the stock to hold, and multiple firms reduced price targets. A disclosed law-firm investigation related to an earlier stock-price decline adds another potential overhang. Stifel downgrade

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.